A Study of LY3023414 and Necitumumab in Squamous Lung Cancer

NCT02443337 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

31

Enrollment

INDUSTRY

Sponsor class

Stopped The study stopped due to lack of efficacy.

Conditions

Non-small Cell Lung Cancer Metastatic

Interventions

DRUG: LY3023414
DRUG: Necitumumab

Sponsor

Eli Lilly and Company

Collaborators

[object Object]